FEuropean Testing Week 2022
 

We are excited to partner with European Testing Week to sponsor 
outreach testing projects for HIV, Hepatitis, and STIs.
 

 

Sign up for a chance to use a GeneXpert system during the week of 
21-28 November 2022. Applications are due on the 1st of October 2022.

Twelve sites will be selected and each will be offered one GeneXpert IV system and up to 100 tests to use in their facility at no charge.

Key selection criteria: 

  • Participants must have a genuine interest in near-patient* testing to improve patient management and healthcare outreach.
  • Testing must be performed in near-patient* settings such as community clinics, sexual health centres, mobile outreach programs, or harm reduction programs.

See how other testing sites are already experiencing the impact of on-site, same-day test results in their service.
 


European Testing Week (ETW) is a Europe-wide outreach campaign that encourages the public, partner organizations, communities, and public health institutes throughout the WHO European Region to unite for one week, to increase participation in voluntary testing for viral hepatitis, HIV, and sexually transmitted infections (STIs).

Sign Up

I would like to be part of the Cepheid Community and I understand and consent to receive information about products and services, invitations to virtual and in-person events such as workshops and webinars and educational content from Cepheid and similar information from Cepheid’s affiliates and representatives.

*required fields
Cepheid respects your privacy, and values the relationship with our customers, partners, and associates. Your personal data may be processed by Cepheid, its affiliates, representatives and other Danaher companies for business and marketing purposes. You can review Cepheid Privacy Policy online for additional information on your rights and how we use and share personal data we collect on our websites and other channels. Your consent to receiving Cepheid news can be withdrawn at any time. Building a relationship of trust is important to us and we will happily help with any questions on your personal data processing addressed to Privacy.officer@cepheid.com

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.
* Near-patient setting indicates decentralized testing by trained users.
Consult the instructions in the systems user manual and individual Cepheid tests’ package inserts for complete product information.
 
Terms and Conditions
Cepheid Europe SAS, a company having its registered office at Vira Solelh 81470 Maurens-Scopont, France, supports this European Testing week.
Participation is free of charge and is only open to non-profit organizations located in the European Union. Only one participation per organization will be accepted.
Participation is subject to a two-step application process. 
First, the applicant must fill in the requested information section available on this page. This first step is open only from the start day of launch till the 1st of October at 24:00. 
Second, only applicants who have completed the first step form will be contacted by a Cepheid representative to finalise the application and will answer some questions about their organization, the type of services provided, the epidemiological situation, testing, and challenges.
The application will be registered only after completing the two steps.
After this process, Cepheid will select 12 sites in Europe based on their genuine interest in near-patient testing to improve patient management and healthcare outreach. 
Selected organizations will be contacted by a Cepheid representative and will be offered one GX4- 4 for one week & up to 100 tests for free, provided that the organization signs a Test Kit User Agreement with Cepheid.
Selection cannot be transferred to other organizations and will under no circumstances be refunded in cash.
Cepheid reserves the right to cancel, suspend or modify the conditions of participation at any time without notice.

 

About Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's (NYSE: DHR) Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

For more information, visit https://www.cepheid.com/en.